Zollinger-Ellison syndrome in 2006: Concepts from a clinical point of view

Panminerva Medica

Volumn 48, Issue 1, 2006, Pages 33-40

  Pellicano, R ^a   De Angelis, C ^a   Resegotti, A ^a   Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Gastrinoma; Neuroendocrine neoplasms; Proton pump inhibitors; Somatostatin, analogues and derivates; Zollinger Ellison syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GASTRIN; INTERFERON; PROTON PUMP; SOMATOSTATIN;

ARTIFICIAL EMBOLISM; DRUG ANTAGONISM; GASTRINOMA; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SECRETION; STOMACH ACID; ZOLLINGER ELLISON SYNDROME;

ANTINEOPLASTIC AGENTS; EMBOLIZATION, THERAPEUTIC; GASTRIC ACID; GASTRINOMA; GASTRINS; HUMANS; INTERFERONS; PROGNOSIS; PROTON PUMPS; SOMATOSTATIN; ZOLLINGER-ELLISON SYNDROME;

EID: 33745051385     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Campana D, Piscitelli L, Mazzotta E, Bonora M, Serra C, Salomone L et al. Zollinger-Ellison syndrome. Diagnosis and treatment. Minerva Med 2005;96:187-206.
2. Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2006;7:169-75.
3. Chandrasekharappa SC, Guru SC, Manickamp P, Olufemi SE, Collins FS, Emmert-Buck MR et al. Positional cloning of the gene for multiple endocrine neoplasia type 1 (MEN 1). Science 1997;276:404-7.
4. Tomassetti P, Campana D, Piscitelli L, Mazzotta E, Brocchi E, Pezzilli R et al. Treatment of Zollinger-Ellison sindrome. World J Gastroenterol 2005;11:5423-32.
5. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, Brooks FA, DiMagno EP, Gardner JD, Lebenthal E, Reber HA et al. editors. The pancreas: biology, pathobiology, and disease. New York: Raven Press; 1993.p.931-78.
6. Schubert ML. Gastric secretion. Curr Opin Gastroenterol 2005;21:636-43.
7. Pellicano R, Fagoonee S, Palestro G, Rizzetto M, Ponzetto A. Intestinal metaplasia, dysplasia, gastric cancer and Helicobacter pylori: epidemiological observations. Minerva Med 2005;96:1-10.
8. Weber HC, Venzon DJ, Jensen RT, Metz DC. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylon, and proton pump inhibitor therapy. Gastroenterology 1997;112:84-91.
9. Watanabe T, Matsushima Y, Nakase H, Iwano M, Hosotani R, Imamura Metal. Effects of Helicobacter pylori infection on Zollinger-Ellison syndrome. J Gastroenterol 2000;35:735-41.
10. Cameron AJ, Hoffman HN. Zollinger-Ellison syndrome. Clinical features and long-term follow-up. Mayo Clin Proc 1974;49:44-51.
11. Modlin IM, Kidd M, Latich I, Zikusova MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51.
12. Nikou GC, Toubanakis C, Nikolau P, Giannatou E, Marinou K, Safioleas M et al. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005;52:1668-76.
13. Lowe RC, Wolfe MM. The pharmacological management of gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2004;50:227-37.
14. Papa A, Urgesi R, Grillo A, Danese S, Guglielmo S, Roberto I et al. Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD). Minerva Gastroenterol Dietol 2004;50:215-26.
15. Pellicano R, Repici A, Rizzetto M. Strategies for the diagnosis of gastro-esophageal reflux disease. Minerva Gastroenterol Dietol 2004;50:193-203.
16. Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med 1989;111:713-22.
17. Yamamoto C, Aoyagi K, Iwata K, Morita I, Hotokezaka M, Funakoshi S et al. Double doses of secretin contribute to diagnosis of Zollinger-Ellison syndrome in secretin and selective arterial secretion injection tests-a case report. Dig Dis Sci 2005;50:2034-6.
18. Imamura M, Komoto I, Ota S. Changing treatment strategy for gastronoma in patients with Zollinger-Ellison sindrome. World J Surg 2006;30:1-11.
19. De Angelis C, Repici A, Arena V, Pellicano R, Rizzetto M. Preoperative endoscopic ultrasonography in decision making and management for pancreatic endocrine tumours: a 6-year experience. Endoscopy 1998;30 Suppl 1:A182-A186.
20. Jensen RT, Gibril F. Somatostatin receptor scintigraphy in gastrinomas. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:179-85.
21. Jensen RT, Gardner JD, Raufman JP, Pandol SJ, Doppman JL, Collen MJ. Zollinger-Ellison syndrome: current concepts and management. Ann Intern Med 1983;98:59-75.
22. Bartsch DK, Fendrick V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005;242:757-66.
23. Pellicano R. The proton pump inhibitors, a family of drugs in continuous expansion. Minerva Gastroenterol Dietol 2000;46:231-41.
24. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1987;317:1200-9.
25. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006;98:4-19.
26. Metz DC, Comer GM, Soffer E, Forsmark CE, Cryers B, Chey W et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006;23:437-44.
27. Guzzo JL, Duncan M, Bass BL, Bochicchio GV, Napolitano LM. Severe and refractory peptic ulcer disease: the diagnostic dilemma. Case report and comprehensive review. Dig Dis Sci 2005;50:1999-2008.
28. Ruszniewski P, Laucournet H, Elouaer-Blanc L, Mignon M, Bonfils S. Long-acting somatostatin (SMS 201-995) in the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas 1988;3:145-52.
29. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumours. Am J Gastroenterol 1998;93:1468-71.
30. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000;14:557-60.
31. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A et al. Prospective study of the antitumour efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002;94:331-43.
32. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumours with somatostatin analogues. N Engl J Med 2000;343:551-4.
33. Lehmann FS, Hildebrand P, Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs 2003;63:1785-97.
34. Paganelli O, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426-34.
35. Thompson NW, Bondeson AG, Bondeson L, Vinik A. The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery 1989;106:1081-5.
36. Fraker DL, Norton JA, Alexander HR, Venzon DJ, Jensen RT. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 1994;220:320-8.
37. Fraker DL, Norton JA, Saeed ZA, Maton PN, Gardner JD, Jensen RT. A prospective study of perioperative and postoperative control of acid hypersercretion in patients with Zollinger-Ellison syndrome undergoing gastrinoma resection. Surgery 1988;104:1054-63.
38. Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998;243:495-500.
39. Akerstrom G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumours of the pancreas in MEN 1. Langenbecks Arch Surg 2002;386:558-69.
40. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998;243:477-88.
41. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 1993;17:455-62.
42. Warner RRP. Enteroendocrine tumours other than carcinoid: a review of clinically significant advances. Gastroenterology 2005;128:1668-84.
43. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987;14:343-53.
44. von Schrenck T, Howard JM, Doppman JL, Norton JA, Maton PN, Smith FP et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988;94:1326-34.
45. Rougier P, Mitry E. Chemotherapy in the treatment of neuroendocrine malignant tumours. Digestion 2000;62 Suppl 1:73-8.
46. Carrasco CH, Chuang VP, Wallace S. Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 1983;149:79-83.
47. Chang TMS. The role of artificial cells in cell and organ transplantation in regenerative medicine. Panminerva Med 2005;47:1-9.